Teva settles Ortho Tri-Cyclen Lo patent dispute

Teva will obtain a release for past sales of its generic version of the oral contraceptive, in exchange for a royalty payment.

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA) has entered into a definitive agreement with Ortho-McNeil-Janssen. The agreement settles the patent infringement lawsuit in the US District Court for the District of New Jersey related to Teva’s generic version of the oral contraceptive, Ortho Tri-Cyclen Lo.

Under the terms of the settlement, Teva will obtain a release for past sales of its generic product, in exchange for an undisclosed royalty payment. Teva also will obtain a license to re-enter the market on December 31, 2015, or earlier in certain circumstances.

The settlement will not become effective until the court enters a proposed consent judgment upholding the validity and enforceability of Ortho’s patent.

Teva's shares rose 0.32% on Friday to $50.35 giving a market cap of $42.95 billion.

Published by Globes [online], Israel business news - www.globes-online.com - on July 26, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018